Skip to main content
SpringerLink
Log in

Aromatase Inhibitors as Chemopreventives of Breast Cancer

  • Chapter
Cancer Chemoprevention

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 245 Accesses

Abstract

Aromatase is a cytochrome P450 enzyme present in the endoplasmic reticulum (ER) which is responsible for the synthesis of steroidal estrogens. It appears that a single aromatase gene codes for the enzyme in all tissues, but, as discussed here, the control of this gene is tissue-specific according to the usage of a number of different promoters (1). Aromatase catalyzes the conversion of androstenedione (the preferred substrate) and testosterone to estrone, then to estradiol. The conversion of estrone to estradiol the most potent estrogen is reversible, and is catalyzed by the 17(β hydroxysteroiddehydrogenase enzyme system (Fig. 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Simpson ER, Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 2002;57:317–338.

    Article  PubMed  CAS  Google Scholar 

  2. Santen RJ, Samojlik E, Wells SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 1980;51:473–477.

    Article  PubMed  CAS  Google Scholar 

  3. Harris AL, Dowsett M, Jeffcoate SL, et al. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 1982;55:718–722.

    Article  PubMed  CAS  Google Scholar 

  4. Stein RC, Dowsett M, Hedley A, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990;62:679–683.

    Article  PubMed  CAS  Google Scholar 

  5. Sinha S, Kaseta J, Santner SJ, et al. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat 1998;48:45–51.

    Article  PubMed  CAS  Google Scholar 

  6. Shetty G, Krishnamurthy H, Krishnamurthy HN, et al. Effect of estrogen deprivation on the reproductive physiology of male and female primates. J Steroid Biochem Mol Biol 1997;61:157–166.

    Article  PubMed  CAS  Google Scholar 

  7. Mitwally MF, Casper RF. Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol 2002;14:255–263.

    Article  PubMed  Google Scholar 

  8. Longcope C, Baker R, Johnston CC Jr. Androgen and estrogen metabolism: relationship to obesity. Metabolism 1986;35:235–237.

    Article  PubMed  CAS  Google Scholar 

  9. Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II Correlation of the extent of conversion of androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476–479.

    Article  PubMed  CAS  Google Scholar 

  10. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001;79:93–102.

    Article  PubMed  CAS  Google Scholar 

  11. Miller WR. Importance of intratumoural aromatase and its susceptibility to inhibitors, in Aromatase Inhibition-Then, Now and Tomorrow. Dowsett M, ed., Partenon Publishing, London 1994, pp. 43–53.

    Google Scholar 

  12. Silva MC, Rowlands MG, Dowsett M, et al. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989;49:2588–2591.

    PubMed  CAS  Google Scholar 

  13. Lipton A, Santen RJ, Santner SJ, et al. Prognostic value of breast cancer aromatase. Cancer 1992;70:1951–1955.

    Article  PubMed  CAS  Google Scholar 

  14. Miller WR, Mullen P, Telford J, Dixon JM. Clinical importance of intratumoral aromatase. Breast Cancer Res Treat 1998;49 Suppl 1:S27-S32.

    Google Scholar 

  15. Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996;17:2279–2284.

    Article  PubMed  CAS  Google Scholar 

  16. Endogenous Hormones and Breast Cancer Collaborative Group (EHBCCG). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606–616.

    Article  Google Scholar 

  17. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.

    Article  PubMed  CAS  Google Scholar 

  18. Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update 2001;7:273–281.

    Article  PubMed  CAS  Google Scholar 

  19. Stuart-Harris RC, Smith IE. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984;11:189–204.

    Article  PubMed  CAS  Google Scholar 

  20. Brodie A, Long B. Aromatase inhibition and inactivation. Clin Cancer Res 2001;12 Supp1:4343s-4349s.

    Google Scholar 

  21. Di Salle E, Giudici D, Ornati G, et al. 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J Steroid Biochem Mol Biol 1990;37:369–374.

    Article  PubMed  Google Scholar 

  22. Dowsett M, Cunningham DC, Stein RC, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989;49:1306–1312.

    PubMed  CAS  Google Scholar 

  23. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a Phase I study. Clin Cancer Res 1997;3:1101–1108.

    PubMed  CAS  Google Scholar 

  24. Kao YC, Cam LL, Laughton CA, Zhou D, Chen S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res 1996;56:3451–3460.

    PubMed  CAS  Google Scholar 

  25. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000;1 Suppl 1:S9-S14.

    Article  PubMed  Google Scholar 

  26. Wing LY, Garrett WM, Brodie AM. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7, 12dimethylbenz(a)anthracene-induced mammary tumors. Cancer Res 1985;45:2425–2428.

    PubMed  CAS  Google Scholar 

  27. Wilkinson JR, Williams JC, Singh D, et al. Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Cancer Res 1986;46:4862–4865.

    PubMed  CAS  Google Scholar 

  28. Schieweck K, Bhatnagar AS, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993;44:633–636.

    Article  PubMed  CAS  Google Scholar 

  29. Lu Q, Yue W, Wang J, et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998;50:63–71.

    Article  PubMed  CAS  Google Scholar 

  30. Lee K, Macaulay VM, Nicholls JE, et al. An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells. Int J Cancer 1995;62:297–302.

    Article  PubMed  CAS  Google Scholar 

  31. Dukes M. The relevance of preclinical models to the treatment of postmenopausal breast cancer. Oncology 1997;54 Suppl 2:6–10.

    Article  PubMed  Google Scholar 

  32. Liu XD, Xie L, Zhong Y, Li CX. Gender difference in letrozole pharmacokinetics in rats. Acta Pharmacol Sinica 2000;2:680–684.

    Google Scholar 

  33. Lubet RA, Steele VE, DeCoster R, et al. Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1998;19:1345–1351.

    Article  PubMed  CAS  Google Scholar 

  34. Gunson DE, Steele RE, Chau RY. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer 1995;72:72–75.

    Article  PubMed  CAS  Google Scholar 

  35. Gunson DE, Bell R, Sahota PS, Hsu HH. Inhibition of spontaneous mammary tumors by CGS 20267, an aromatase inhibitor, in female Sprague-Dawley rats. Toxicol Pathol 1996;24:789.

    Google Scholar 

  36. Tekmal RR, Ramachandra N, Gubba S, et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 1996;56:3180–3185.

    PubMed  CAS  Google Scholar 

  37. Mandava U, Kirma N, Tekmal RR. Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affect-ing normal physiology. J Steroid Biochem Mol Biol 2001;79:27–34.

    Article  PubMed  CAS  Google Scholar 

  38. Feinlieb M. Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 1968;41:315–329.

    Google Scholar 

  39. Nissen-Meyer R. Primary breast cancer: the effect of primary ovarian irradiation. Ann Oncol 1991;2:343–346.

    PubMed  CAS  Google Scholar 

  40. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453–461.

    PubMed  CAS  Google Scholar 

  41. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399–1411.

    PubMed  CAS  Google Scholar 

  42. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000–2011.

    PubMed  CAS  Google Scholar 

  43. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357–3366.

    PubMed  CAS  Google Scholar 

  44. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247–2258.

    Article  PubMed  CAS  Google Scholar 

  45. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–2606.

    PubMed  CAS  Google Scholar 

  46. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527–1532.

    Article  PubMed  CAS  Google Scholar 

  47. ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139.

    Article  Google Scholar 

  48. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351:1451–1467.

    Article  Google Scholar 

  49. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000;26:411–414.

    Article  PubMed  CAS  Google Scholar 

  50. MacNeill FA, Jones AL, Jacobs S, et al. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992;66:692–697.

    Article  PubMed  CAS  Google Scholar 

  51. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751–757.

    Article  PubMed  CAS  Google Scholar 

  52. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089–2093.

    PubMed  CAS  Google Scholar 

  53. ATAC Trialists’ Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317–324.

    Article  Google Scholar 

  54. Dowsett M, Pfister C, Johnston SR, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999;5:2338–2343.

    PubMed  CAS  Google Scholar 

  55. Stuart-Harris RC, Smith IE. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984;11:189–204.

    Article  PubMed  CAS  Google Scholar 

  56. Plourde PV, Dyroff M, Dowsett M, et al. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995;53:175–179.

    Article  PubMed  CAS  Google Scholar 

  57. Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999;35:208–213.

    Article  PubMed  CAS  Google Scholar 

  58. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol. Biomark Prey 2002;11:614–621.

    CAS  Google Scholar 

  59. Engan T, Krane J, Johannessen DC, et al. Plasma changes in breast cancer patients during endocrine therapy lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995;36:287–297.

    Article  PubMed  CAS  Google Scholar 

  60. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510–1513.

    Article  PubMed  CAS  Google Scholar 

  61. Harper-Wynne CL, Sacks NP, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002b;20:1026–1035.

    Article  CAS  Google Scholar 

  62. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Mineral Res 2002;17:172–178.

    Article  CAS  Google Scholar 

  63. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  64. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and post-menopausal women. J Clin Oncol 1996;14:78–84.

    PubMed  CAS  Google Scholar 

  65. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–432.

    Article  PubMed  CAS  Google Scholar 

  66. Harper-Wynne C, Dowsett M. Recent advances in the clinical application of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;760:179–186.

    Article  Google Scholar 

  67. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529–1542.

    Article  PubMed  CAS  Google Scholar 

  68. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456–462.

    Article  PubMed  CAS  Google Scholar 

  69. Tarone RE, Chu KC. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control 2002;13:7–14.

    Article  PubMed  Google Scholar 

  70. Huang WY, Newman B, Millikan RC, et al. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151:703–714.

    Article  PubMed  CAS  Google Scholar 

  71. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699–706.

    Article  PubMed  CAS  Google Scholar 

  72. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–1886.

    Article  PubMed  CAS  Google Scholar 

  73. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541–1548.

    Article  PubMed  CAS  Google Scholar 

  74. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600–607.

    Article  PubMed  CAS  Google Scholar 

  75. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358–366.

    Article  PubMed  CAS  Google Scholar 

  76. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  77. Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 2002;160:597–604.

    Article  PubMed  Google Scholar 

  78. Shoker BS, Jarvis C, Sibson DR, et al. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188:237–244.

    Article  PubMed  CAS  Google Scholar 

  79. Rutter CM, Mandelson MT, Laya MB, et al. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171–176.

    Article  PubMed  CAS  Google Scholar 

  80. Chow CK, Venzon D, Jones EC, et al. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomark Prey 2000;9:917–921.

    CAS  Google Scholar 

  81. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Nall Cancer Inst 1995;87:1622–1629.

    Article  CAS  Google Scholar 

  82. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670–675.

    Article  PubMed  CAS  Google Scholar 

  83. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Nall Cancer Inst 1998;90:1292–1299.

    Article  CAS  Google Scholar 

  84. Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000;19:1329–1333.

    Article  PubMed  CAS  Google Scholar 

  85. Haiman CA, Hankinson SE, Spiegelman D, et al. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prey 2002;11:215–216.

    CAS  Google Scholar 

  86. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659–2669.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Mitchell Dowsett PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judy E. Garber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Institutes of Health, Rockville, MD, USA

    Gary J. Kelloff MD  & Ernest T. Hawk MD, MPH  & 

  2. CCS Associates, Mountain View, CA, USA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dowsett, M., Garber, J.E. (2004). Aromatase Inhibitors as Chemopreventives of Breast Cancer. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-767-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-767-3_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-342-8

  • Online ISBN: 978-1-59259-767-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation